Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
Inclusion Criteria
INCLUSION
To be eligible, volunteers must:
- Have stage IV carcinoma of the breast that has been microscopically confirmed
- Be age > 18
- Be fully active or ambulatory with symptoms but able to do light work
- Have a life expectancy of > 16 weeks
- Be > 2 weeks from prior surgery; > 3 weeks from radiation therapy to the pelvis,
spine or long bones; > 3 weeks from prior chemotherapy (> 6 weeks for mitomycin C or
nitrosureas) and > 2 weeks from prior hormonal therapy
- Have had one or less prior regimens for metastatic disease
- Have measurable (bidimensionally) or evaluable disease that is in an area that has
not been radiated
EXCLUSION
Patients are not eligible if they:
- Have rapidly progressing liver or lung metastases or uncontrolled central nervous
system metastases
- Are medically unstable
- Are pregnant, nursing or unwilling to employ adequate contraception
- Have pre-existing clinically significant peripheral neuropathy except for
abnormalities due to cancer
- Have psychological, familial, sociological or geographical conditions that do not
permit weekly medical follow-up and compliance with the study protocol
- Have hypersensitivity to E. Coli-derived proteins, Filgrastim, or any of its
components
- Have had prior therapy with Navelbine